Skip to main content
Skip to content
Case File
sd-10-EFTA01354450Dept. of JusticeOther

EFTA Document EFTA01354450

GLDUSI 43 Henry Nicholas SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary i Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services Use of

Date
Unknown
Source
Dept. of Justice
Reference
sd-10-EFTA01354450
Pages
1
Persons
0
Integrity
Loading PDF viewer...

Summary

GLDUSI 43 Henry Nicholas SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary i Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services Use of

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
GLDUSI 43 Henry Nicholas SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary i Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services Use of leverage No Average age at purchase 9 years Description - Motivated quality GP aiming to recapitalize and extend their 2007 mid- market pan-European fund while providing liquidity to LPs - Key value driver is largest independent UK premium distributor in its segment, well positioned to benefit from market tailwinds - Second largest asset is a network of medical and cosmetics UK clinics with a private and affluent customer base - The portfolio also includes an Italian digital marketing company and a management consulting company with blue chip customers - Glendower Capital retains discretion on use of follow-on capital Investment rationale / Glendower Team angle Glendower Team angle - Ability to quickly deliver a bespoke solution leveraging Glendower's track record in complex transactions - Ability to perform extensive diligence, including onsite visits, full access to companies' management and industry specialists - Long 15-year relationship with the GP founder Investment rationale - Four well-invested companies positioned to capture growth opportunities arising from ongoing changes in industry landscape - Key value driver led by industry veteran with a solid track record - Value-add potential from recently implemented cost efficiency initiatives - Opportunity to invest in identified follow-ons at closing, and to contribute additional capita! to exploit market dislocations Fot diecknsaon perposesr4y. The irra: groing pteserced above I . s. rimi clostei. argi niere is no guarancee investineol cenbecae or form pag og a lunge invosted portfcCio or that g lei be avaliatge or. ante fugene due diligence, prove ststable for SOF This. Blide hauld be mnd and tevie-wc-d in conjunetion with the -Imponant Information and "Important Perframance Intormebon and • Notes to Investment Pedormance sectior*. Glendower Capital STRICTLY CONFIDENTIAL CONFIDENTIAL - PURSUANT TO FED. R. CRIM. P. 6(e) DB-SDNY-0039044 CONFIDENTIAL SDNY_GM_00185228 EFTA01354450

Related Documents (6)

OtherUnknown

1First Bank

DOJ EFTA Data Set 10 document EFTA01268970

130p
Dept. of JusticeMar 11, 2011

FBI Bruce E Ivins Investigation

010347Anthrax Page 1 of 1274 (Rev. 01-31-2003) FEDERAL BUREAU OF INVESTIGATION o Precedence: To: From: ROUTINE Date: 02/01/2007 Washington Field Washington Field Squad AMX-1/~VRA Contact: SAl ~--~~--------------------------~ b6 Approved By: Drafted By: Case ID #: 279A-WF-222936 ~79A-WF-222936-BEI (Pending) .. {{t;1%l.O (Pending)-1 279A-WF-222936-BEI-FISUR (Pending) -/ Title: AMERITHRAX; MAJOR CASE 184 ....?,-;-~"$'- Synopsis: Opening of sub-files for the'--'.:9a'ptioned matter. D

1274p
Dept. of JusticeMar 11, 2011

FBI USAMRID Investigation

011621Anthrax Page 1 of 1446 o I 2792\-WF-222936-'-USAMRIID - \\OC o I [he followijg investigation was conducted by Special Agent (SA)_ _of the federal Bureau of Investigation (FBI) on February 24, 2005: ? The United States Army Medical Research Institute of Infectious Diseases (USAMRIID) Keycard Access records from 1998 through 2002 were queried f r v' ? ? ? scientist nd visitin scient'st both ?rom the who have p eviously been identified as visiting USAMRIID circa May 1998. ;11 available

1446p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01382731

S- I/A Table of Contents Perquisite and Personal Benefits Tax Financial Defined Contribution Life Insurance Gross-lip Payments Severance Payments Relocation Benefits Other Compensation Total Name Blanninu(S) Plain(S) (IXS) (2)(S) (3XS) OBS) (5)(S) (5) Frank l. Bisignano 18.812 265 4.902 270,017 — 52,384 186.819 533,199 Michael K. bleborak — — 1.183 — — — — 1.183 Ray E. Winbomc — 984 1.683 2.085,768 - - 2,088.435 Cynthia A. Armine-Klein — 673

1p
Dept. of JusticeAug 22, 2017

15 July 7 2016 - July 17 2016 working progress_Redacted.pdf

Kristen M. Simkins From: Sent: To: Cc: Subject: Irons, Janet < Tuesday, July 12, 2016 10:47 AM Richard C. Smith     Hello Warden Smith,     mother is anxious to hear the results of your inquiry into her daughter's health.   I'd be grateful if you could  email or call me at your earliest convenience.  I'm free today after 2 p.m.  Alternatively, we could meet after the Prison  Board of Inspectors Meeting this coming Thursday.    Best wishes,    Janet Irons    1 Kristen M. Simkins From: Sent:

1196p
Dept. of JusticeOtherUnknown

EFTA Document EFTA01364547

GLOUS238 SOUTHERN FINANCIAL LLC SOF IV — Project Klein Exclusive deal Expected Glosing Date: June 2018 El Fund Secondary i Secondary K Single Asset Deal Seller type: Alternative funds Key investment data Transaction summary Invested Capital at dose E60-100m (US$80-120m) Number of companies 4 Discount to NAV at close >5% Strategy Mid-market buyout Gross multiple at close 1.1x Region Europe / UK 0/0 funded at close 80% Industries Business services / Healthcare services

1p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.